Next generation HPC/QC in silico drug discovery platform for de novo design

ATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027.

Subsidie
€ 2.500.000
2022

Projectdetails

Introduction

ATLAS is a powerful in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing. The platform is the result of decades of research by leading experts in molecular dynamics. The technology is grounded on over 100 peer-reviewed papers and two ERC grants.

Achievements

Our beta code has gathered important accolades, including:

  • The prestigious ATOS-Joseph Fourier prize
  • First place at the foremost rational drug design competition, the SAMPL challenge

Benefits of ATLAS

ATLAS can replace costly and laborious experiments. It can even run entire drug discovery campaigns in silico, reducing cycle times and costs by at least 50%.

Future Goals

By 2027, we will have a 35-project portfolio, and the first ATLAS-generated compound will reach the clinic. Thereafter, our objective is to generate a new candidate every 18 months.

Team Expansion and Market Strategy

That year, our team will surpass 50 people, and we will expand into the US market. We aim at securing a leadership position in the nascent in-silico drug discovery market.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.500.000
Totale projectbegroting€ 4.249.375

Tijdlijn

Startdatum1-9-2022
Einddatum31-8-2024
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • QUBIT PHARMACEUTICALSpenvoerder

Land(en)

France

Vergelijkbare projecten binnen EIC Accelerator

EIC Accelerator

The first utility-oriented, agnostic software platform for quantum-centric drug discovery

Kvantify is developing Kvaser, a user-friendly quantum software tool for R&D scientists to perform advanced molecular simulations, enhancing drug discovery with speed and precision.

€ 2.499.999
EIC Accelerator

BioSim M2M: Molecules to Medicine

BioSimulytics' BioSim M2M technology accelerates pharmaceutical R&D by predicting stable crystal structures and binding poses, reducing analysis time from 3 months to 3 weeks.

€ 2.499.525
EIC Accelerator

Multi-omic data driven drug discovery and indication prioritisation platform in oncology

mCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies.

€ 2.495.788
EIC Accelerator

Human-Centric AI platform for heALth and Life sciences

Abzu ApS aims to revolutionize AI in pharma with the QLattice, a user-friendly, explainable platform that enhances R&D efficiency and reduces costs, supported by EIC funding.

€ 2.495.099
EIC Accelerator

Closed-loop deep learning in early-stage drug discovery - cloud platform for targeted protein degradation

Celeris Therapeutics leverages deep learning to develop a web platform for degrading undruggable proteins, aiming to revolutionize drug discovery for incurable diseases like Alzheimer's and cancer.

€ 2.500.000

Vergelijkbare projecten uit andere regelingen

ERC Advanced...

Automated, miniaturized and accelerated drug discovery: AMADEUS

AMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility.

€ 3.409.401
Mkb-innovati...

Drug Discovery Intelligence

Het project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties.

€ 20.000
ERC Starting...

Artificial Scientific Discovery of advanced Quantum Hardware with high-performance Simulators

ARTDISQ aims to leverage AI and high-performance simulators to automate the design of advanced quantum experiments, enhancing discoveries in gravitational wave detection and imaging systems.

€ 1.499.221
ERC Starting...

Turning gold standard quantum chemistry into a routine simulation tool: predictive properties for large molecular systems

This project aims to develop advanced quantum simulation methods for large molecules, enhancing predictive power and efficiency to study complex biochemical interactions and reactions.

€ 1.175.215
Mkb-innovati...

Cloudplatform for High Content Imaging

Core Life Analytics ontwikkelt een cloudplatform voor onafhankelijke onderzoekers om snel en kosteneffectief HC data-analyse uit te voeren.

€ 20.000